


Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete If Known	
 <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)</p>		Application Number	10/500,884
		Filing Date	July 7, 2004
		First Named Inventor	Richard Compans
		Group Art Unit	
		Examiner Name	
		Attorney Docket Number	EU 01083
Sheet	2 of 9		

OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
/TM/		ALMARSSON, et al., "Synthesis and characterization of an octacationic iron(III) tetraphenylporphyrin, which is soluble in water and non-m-oxo dimer forming" <i>J. Am. Chem. Soc.</i> 117: 4524-4532 (1995).	
		ARAI, et al., "Spatially close porphyrin pair linked by the cyclic peptide Gramicidin" <i>S. J. Chem. Soc. Chem. Commun.</i> 1503-1504 (1999).	
		ARAI, et al., "Synthesis of a membrane-spanning lipophilic porphyrin with links to two alamethicin fragments on each face" <i>J. Chem. Soc. Perkin Trans. 2</i> 1381-1390 (2000).	
		ARGYRIS, et al., "The connection domain is implicated in metalloporphyrin binding and inhibition of HIV reverse transcriptase" <i>J. Biol. Chem.</i> 274: 1549-1556 (1999).	
		ARGYRIS, et al., "Mutagenesis of key residues identifies the connection subdomain of HIV-1 reverse transcriptase as the site of inhibition by heme" <i>Eur. J. Biochem.</i> 268: 925-931 (2001).	
		ASANAKA, et al., "Anti-HIV activity of protoporphyrin" <i>AIDS</i> 3, 403-404 (1989).	
		CAROFIGLIO, et al., "Synthesis, characterization, and supramolecular properties of a hydrophilic porphyrin-beta-cyclodextrin conjugate" <i>J. Org. Chem.</i> 65: 9013-9021 (2000).	
		CASAS, et al., "Synthesis of cationic metalloporphyrin precursors related to the design of DNA cleavers" <i>J. Org. Chem.</i> 58: 2913-2917 (1993).	
		CHACKERIAN, et al., "Characterization of a CD4-expressing macaque cell line that can detect virus after a single replication cycle and can be infected by diverse simian immunodeficiency virus isolates" <i>Virology</i> 213: 386-394 (1995).	
		CHALOIN, et al., "Improvement of porphyrin cellular delivery and activity by conjugation to a carrier peptide" <i>Bioconjug. Chem.</i> 12: 691-700 (2001).	
/TM/		CLARKE, et al., "Microflora changes with the use of a vaginal microbicide" <i>Sex. Transm. Dis.</i> 29: 288-293 (2002).	

Examiner's Signature	/Traviss McIntosh III/ (06/24/2007)	Date Considered	06/24/2007
----------------------	-------------------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete If Known	
 <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)</p>		Application Number	10/500,884
		Filing Date	July 7, 2004
		First Named Inventor	Richard Compans
		Group Art Unit	
		Examiner Name	
		Attorney Docket Number	EU 01083
Sheet	3 of 9		

OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
/TM/		COHEN, J. "AIDS therapies - Exploring how to get at and eradicate hidden HIV" <i>Science</i> 279: 1854-1855 (1998).	
		CORNIA, et al., "Facile entry to 5,10,15,20-tetra-C-glycosylporphyrins" <i>J. Org. Chem.</i> 59: 1226-1230 (1994).	
		CSIK, et al., "Glycosylated derivatives of tetraphenyl porphyrin: photophysical characterization, self-aggregation and membrane binding" <i>J. Photochem. Photobiol. B</i> 44: 216-224 (1998).	
		DANCIL, et al., "Synthesis and aggregation of cationic porphyrins" <i>J. Heterocycl. Chem.</i> 34: 749-755 (1997).	
		DEBNATH, et al., "Three-dimensional structure-activity analysis of a series of porphyrin derivatives with anti-HIV-1 activity targeted to the V3 loop of the gp120 envelope glycoprotein of the human immunodeficiency virus type 1" <i>J. Med. Chem.</i> 37: 1099-1108 (1994).	
		DEBNATH, et al., "Anti-HIV-1 activity of carborane derivatives of porphyrins" <i>Med. Chem. Res.</i> 9: 267-275 (1999).	
		DECAMP, et al., "Specific inhibition of HIV-1 protease by boronated porphyrins" <i>J. Med. Chem.</i> 35: 3426-3428 (1992).	
		DECLERCQ, "Strategies in the design of antiviral drugs" <i>Nat. Rev. Drug Discov.</i> 1: 13-25 (2002).	
		DE LUCA, et al., "New synthetic tools for peptide-tetraphenylporphyrin derivatives" <i>Letters in Peptide Science</i> 5: 269-276 (1998).	
		DE LUCA, et al., "Synthesis and solution characterization of a porphyrin-CCK8 conjugate" <i>Journal of Peptide Science</i> 7: 386-394 (2001).	
		DING, et al., "Synthesis of water-soluble, cationic functionalized metalloporphyrins having a cytotoxic activity" <i>New J. Chem.</i> 14: 421-431 (1990).	
/TM/		DING, et al., "Anti-human immunodeficiency virus effects of cationic metalloporphyrin-ellipticine complexes" <i>Biochem. Pharmacol.</i> 44: 1675-1679 (1992).	
Examiner's Signature	/Traviss McIntosh III/ (06/24/2007)		Date Considered 06/24/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete If Known	
		Application Number	10/500,884
		Filing Date	July 7, 2004
		First Named Inventor	Richard Compans
		Group Art Unit	
		Examiner Name	
Sheet	4	of	9
		Attorney Docket Number	EU 01083

OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
/TM/		DIXON, et al., "Porphyrins as agents against the human immunodeficiency virus" <i>Ann. N. Y. Acad. Sci.</i> 616: 511-513 (1990).	
		DIXON, et al., "Amino- and hydroxytetraphenylporphyrins with activity against the human immunodeficiency virus" <i>Antiviral Chem. Chemother.</i> 3: 279-282 (1992).	
		FEORINO, et al., "Prevention of activation of HIV-1 by antiviral agents in OM-10.1 cells" <i>Antiviral Chem. Chemother.</i> 4: 55-63 (1993).	
		FICHOROVA, et al., "The molecular basis of nonoxynol-9-induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission" <i>J. Infect. Dis.</i> 184: 418-428 (2001).	
		GABOR, et al., "Photoinduced inactivation of T7 phage sensitized by symmetrically and asymmetrically substituted tetraphenyl porphyrin: Comparison of efficiency and mechanism of action" <i>Photochem. Photobiol.</i> 73: 304-311 (2001).	
		GARCIA-ORTEGA and RIBO, "Meso and beta-pyrrole sulfonated porphyrins obtained by sulfonation of 5,15-bis(phenyl)porphyrin" <i>J. Porph. Phthal.</i> 4: 564-568 (2000).	
		GEIER and SASAKI, "The design, synthesis and characterization of a porphyrin-peptide conjugate" <i>Tetrahedron Lett.</i> 38: 3821-3824 (1997).	
		JORI, et al., "Preferential delivery of liposome-incorporated porphyrins to neoplastic cells in tumor-bearing rats" <i>Br. J. Cancer</i> 48: 307-309 (1983).	
		KADISH, et al., "Synthesis and electrochemical reactivity of sigma-bonded and N- substituted cobalt porphycenes" <i>Inorg. Chem.</i> 37: 2693-2700 (1998).	
		KAHL, et al., "Improved methods for the synthesis of porphyrin alcohols and aldehydes from protoporphyrin IX dimethyl ester and their further modification" <i>J. Org. Chem.</i> 62: 1875-1880 (1997).	
/TM/		KASTURI and PLATZ, "Inactivation of lambda phage with 658 nm light using a DNA binding porphyrin sensitizer" <i>Photochem. Photobiol.</i> 56: 427-429 (1992).	
Examiner's Signature: /Traviss McIntosh III/ (06/24/2007) Date Considered: 06/24/2007			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) 		Application Number	10/500,884
		Filing Date	July 7, 2004
		First Named Inventor	Richard Compans
		Group Art Unit	
		Examiner Name	
		Attorney Docket Number	EU 01083
Sheet 5	of 9		

OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
/TM/		KIMPTON and EMERMAN, "Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene" <i>J. Virol.</i> 66: 2232-2239 (1992).	
		KOFOD, P. "The pentaamminemethylcobalt(III) cation - synthesis and spectroscopic characterization" <i>Inorg. Chem.</i> 34: 2768-2770 (1995).	
		KOFOD, et al., "NMR spectroscopic characterization of methylcobalt(III) compounds with classical ligands. Crystal structures of [Co(NH3)(5)(CH3)]S2O6, trans-[Co(en)(2)(NH3)(CH3)]S2O6 (en equals 1,2-ethanediamine), and [Co(NH3)(6)]-mer,trans- [Co(NO2)(3)(NH3)(2)(CH3)](2)-trans-[Co(NO2)(4)(NH3)(2)]" <i>Inorg. Chem.</i> 36: 2258-2266 (1997).	
		LANG, et al., "Photoinduced electron transfer within porphyrin-cyclodextrin conjugates" <i>Tetrahedron Lett.</i> 43: 4919-4922 (2002).	
		LEVERE, et al., "Heme inhibits human immunodeficiency virus 1 replication in cell cultures and enhances the antiviral effect of zidovudine" <i>Proc. Natl. Acad. Sci. USA</i> 88: 1756-1759 (1991).	
		LI, et al., "A series of meso-tris(N-methyl-pyridiniumyl)-(4-alkylamidophenyl) porphyrins: Synthesis, interaction with DNA and antibacterial activity" <i>Biochim. Biophys. Acta</i> 1354: 252-260 (1997).	
		LINDSEY, et al., "Rothmund and Adler-Longo reactions revisited: Synthesis of tetraphenylporphyrins under equilibrium conditions" <i>J. Org. Chem.</i> 52: 827-836 (1987).	
		MARZILLI, et al., "Tentacle porphyrins: DNA interactions" <i>J. Am. Chem. Soc.</i> 114: 7575-7577 (1992).	
		MASCOLA, "Passive transfer studies to elucidate the role of antibody-mediated protection against HIV-1" <i>Vaccine</i> 20: 1922-1925 (2002).	
		MATTHEWS, et al., "Inactivation of viruses with photoactive compounds" <i>Blood Cells</i> 18: 75-88 (1992).	
/TM/		MATTHEWS, et al., "Synthesis of porphyrin alpha,omega-bis(methylamino)peptide constructs" <i>New J. Chem.</i> 23: 1087-1096 (1999).	

Examiner's Signature	/Traviss McIntosh III/ (06/24/2007)	Date Considered	06/24/2007
----------------------	-------------------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/500,884
		Filing Date	July 7, 2004
		First Named Inventor	Richard Compans
		Group Art Unit	
		Examiner Name	
		Attorney Docket Number	EU 01083
Sheet 4	of 9		

OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal; serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
/TM/		MENG, et al., "Porphyrin chemistry pertaining to the design of anti-cancer drugs. Part 2. The synthesis and <i>in vitro</i> tests of water-soluble porphyrins containing, in the <i>meso</i> positions, the functional groups: 4-methylpyridinium, or 4-sulfonatophenyl, in combination with phenyl, 4-pyridyl, 4-nitrophenyl, or 4-aminophenyl" <i>Can. J. Chem.</i> 72: 2447-2457 (1994).	
		MUKUNDAN, et al., "Interactions of an electron-rich tetracationic tentacle porphyrin with calf thymus DNA" <i>Inorg. Chem.</i> 33: 4676-4687 (1994).	
		MUKUNDAN, et al., "DNA tentacle porphyrin interactions: AT over GC selectivity exhibited by an outside binding self-stacking porphyrin" <i>Inorg. Chem.</i> 34: 3677-3687 (1995).	
		NEURATH, et al., "Rapid prescreening for antiviral agents against HIV-1 based on their inhibitory activity in site-directed immunoassays. I. The V3 loop of gp120 as target" <i>Antiviral Chem. Chemother.</i> 2: 303-312 (1991).	
		NEURATH, et al., "Rapid prescreening for antiviral agents against HIV-1 based on their inhibitory activity in site-directed immunoassays. II. Porphyrins reacting with the V3 loop of gp120" <i>Antiviral Chem. Chemother.</i> 3: 55-63 (1992).	
		NEURATH, et al., "Rapid prescreening for antiviral agents against HIV-1 based on their inhibitory activity in site-directed immunoassays. Approaches applicable to epidemic HIV-1 strains" <i>Antiviral Chem. Chemother.</i> 4: 207-214 (1993).	
		NEURATH, et al., "Tin protoporphyrin-IX used in control of heme metabolism in humans effectively inhibits HIV-1 infection" <i>Antiviral Chem. Chemother.</i> 5: 322-330 (1994).	
		NEURATH, et al., "Structural requirements for and consequences of an antiviral porphyrin binding to the V3 loop of the human immunodeficiency-virus (HIV-1) envelope glycoprotein gp120" <i>J. Mol. Recognition</i> 8: 345-357 (1995).	
		NISHINO, et al., "Synthesis of linear amphipathic porphyrin dimers and trimers - an approach to bilayer-lipid membrane-spanning porphyrin arrays" <i>J. Org. Chem.</i> 61: 7534-7544 (1996).	
/TM/		NORTH, et al., "Viral inactivation in blood and red cell concentrates with benzoporphyrin derivative" <i>Blood Cells</i> 18: 129-140 (1992).	
Examiner's Signature: /Traviss McIntosh III/ (06/24/2007) Date Considered: 06/24/2007			


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
 <p>(use as many sheets as necessary)</p>		Application Number	10/500,884
		Filing Date	July 7, 2004
		First Named Inventor	Richard Compans
		Group Art Unit	
		Examiner Name	
Sheet 7 of 9	Attorney Docket Number	EU 01083	

OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
/TM/		NORTH, et al., "Photosensitizers as virucidal agents" <i>J. Photochem. Photobiol. B</i> 17: 99-108 (1993).	
		OWENS and COMPANS, "Expression of the human immunodeficiency virus envelope glycoprotein is restricted to basolateral surfaces of polarized epithelial cells" <i>J. Virol.</i> 63: 978-982 (1989).	
		PETHÖ, et al., "Evidence for formation of DNA-bound protonated porphyrin adducts even at pH 7" <i>J. Chem. Soc. Chem. Commun.</i> 1993: 1547-1548 (1993).	
		PISPISA, et al., "Photophysical and structural features of covalently bound peptide-protoporphyrin-peptide compounds carrying naphthalene chromophores" <i>J. Phys. Chem. B</i> 103: 8172-8179 (1999).	
		RITTER, et al., "Cell fusion activity of the simian immunodeficiency virus envelope protein is modulated by the intracytoplasmic domain" <i>Virology</i> 197: 255-264 (1993).	
		ROCHA-GONSALVES, et al., "New procedures for the synthesis and analysis of 5,10,15,20-tetrakis(sulphophenyl)porphyrins and derivatives through chlorosulphonation" <i>Heterocycles</i> 43: 829-838 (1996).	
		SHELL and HOMBRECHER, "Synthesis and investigation of glycosylated mono- and diarylporphyrins for photodynamic therapy" <i>Bioorg. Med. Chem.</i> 7: 1857-1865 (1999).	
		SEDARATI, et al., "Latent Infection Can be Established with Drastically Restricted Transcription and Replication of the HSV-1 Genome" <i>Virology</i> 192: 687-691 (1999).	
		SHANMUGATHASAN, et al., "Advances in modern synthetic porphyrin chemistry" <i>Tetrahedron</i> 56: 1025-1046 (2000).	
✓		SMITH, et al., "Methyl Deuteration Reactions in Vinylporphyrins: Protoporphyrins IX, 111, and XI11" <i>J. Org. Chem.</i> 51, 666-671 (1986).	
/TM/		SOL, et al., "Synthesis, spectroscopy, and photocytotoxicity of glycosylated amino acid porphyrin derivatives as promising molecules for cancer phototherapy" <i>J. Org. Chem.</i> 64: 4431-4444 (1999).	

Examiner's Signature	/Traviss McIntosh III/ (06/24/2007)	Date Considered	06/24/2007
----------------------	-------------------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete If Known	
		Application Number	10/500,884
		Filing Date	July 7, 2004
		First Named Inventor	Richard Compans
		Group Art Unit	
		Examiner Name	
Sheet	8	of	9
		Attorney Docket Number	EU 01083

OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ⁴
/TM/		SOLLADIE, et al., "Synthesis of multiporphyrinic alpha-polypeptides: towards the study of the migration of an excited state for the mimicking of the natural light harvesting device" <i>Tetrahedron Lett.</i> 41: 6075-6078 (2000).	
		SONG, et al., "Anti-HIV activities of anionic metalloporphyrins and related compounds" <i>Antiviral Chem. Chemother.</i> 8:85-97 (1997).	
		SPIELER, "eaweed compound's anti-HIV efficacy will be tested in southern Africa" <i>Lancet</i> 359:1675 (2002).	
		SRIVASTAVA, et al., "Preparation and purification of tetrasodium meso-tetra(p - sulfophenyl)porphine. An easy procedure" <i>J. Org. Chem.</i> 38: 2103 (1973).	
		STAUDINGER, et al., "Inhibition of human immunodeficiency virus-1 reverse transcriptase by heme and synthetic heme analogs" <i>Proc. Assoc. Am. Physicians</i> 108: 47-54 (1996).	
		STERNBERG, et al., "Porphyrin-based photosensitizers for use in photodynamic therapy" <i>Tetrahedron</i> 54: 4151-4202 (1998).	
		STOJILJKOVIC, et al., "Antimicrobial properties of porphyrins" <i>Expert Opin. Investig. Drugs</i> 10: 309-320 (2001).	
		SUTTER, et al., "Steric and inductive effect on the basicity of porphyrins and on the site of protonation of porphyrin dianions" <i>J. Chem. Soc. Faraday Trans.</i> 89: 495-502 (1993).	
		VZOROV and COMPANS, "Assembly and release of SIV Env proteins with full-length or truncated cytoplasmic domains" <i>Virology</i> 221: 22-33 (1996).	
		VZOROV and COMPANS, "Effect of the cytoplasmic domain of the simian immunodeficiency virus envelope protein on incorporation of heterologous envelope proteins and sensitivity to neutralization" <i>J. Virol.</i> 74: 8219-8225 (2000).	
/TM/		VZOROV, et al., "Inactivation of human immunodeficiency virus type 1 by porphyrins" <i>Antimicrobial Agents and Chemotherapy</i> 46(12): 3917-3925 (2002).	

Examiner's Signature	/Traviss McIntosh III/ (06/24/2007)	Date Considered	06/24/2007
----------------------	-------------------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete If Known	
 <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)</p>		Application Number	10/500,884
		Filing Date	July 7, 2004
		First Named Inventor	Richard Compans
		Group Art Unit	
		Examiner Name	
Sheet 9 of 9	Attorney Docket Number	EU 01083	

OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
/TM/		WEBER, et al., "Chemical condoms' for the prevention of HIV infection: Evaluation of novel agents against SHIV(89.6PD) <i>in vitro</i> and <i>in vivo</i> " <i>AIDS</i> 15: 1563-1568 (2001).	
/TM/		WHITLEY, et al., "Acyclovir with and without prednisone for the treatment of herpes zoster - A randomized, placebo-controlled trial" <i>Annals of Internal Medicine</i> 125: 376-383 (1996).	
/TM/		YUE, et al., "Ni(II) porphyrins binding to anionic polymers investigated by resonance Raman spectroscopy" <i>Inorg. Chem.</i> 30: 3214-3222 (1991)..	
/TM/		ZACHAROPOULOS and PHILLIPS, "Vaginal formulations of carrageenan protect mice from herpes simplex virus infection" <i>Clinical and Diagnostic Laboratory Immunology</i> 4: 465-468 (1997).	
/TM/		ZEITLIN, et al., "Tests of vaginal microbicides in the mouse genital herpes model" <i>Contraception</i> 56: 329-335 (1997).	

Examiner's Signature	/Traviss McIntosh III/ (06/24/2007)	Date Considered	06/24/2007
----------------------	-------------------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.